It is World Pneumonia Day on November 12th. Pneumonia and other acute lower respiratory infections remain the most common causes of childhood death, and illness requiring hospitalization globally. This is despite the effective pneumococcal conjugate vaccine (PCV) being widely available, which points to the varied causation of childhood pneumonia in 2020.
recision (or personalised) Health is being promoted as the future of healthcare. Indeed, precision health is the key theme of the latest MCRI strategic plan and the focus of much attention on campus. One of the key tools in precision health is genomics. During this Grand Round, Prof Colin Robertson will reflect on his extensive experience as a clinician-scientist in paediatric respiratory medicine. In particular, he will focus on the successes and failures of genomics in conditions such as cystic fibrosis and asthma, and he will contend that the key to using genomics to improve patient care is a strong understanding of physiology in health and disease.
RCH is excited to be celebrating Allied Health Professionals Day on 14 October 2020. Allied Health Professionals Day first began in the UK in 2018 and has since become an international event to recognise and celebrate the Allied Health Professional community.
Vernon Collins Oration 2020
Championing child rights amidst the chaos of COVID-19
Professor Elizabeth Elliott, AM
The Consultative Council on Obstetric and Paediatric Mortality and Morbidity (CCOPMM) monitors the causes and factors involved in all child deaths throughout Victoria, and provides recommendations to Government, health care professionals and the community. In recent years the Council has identified the social and economic gradient in risk of child deaths, which includes virtually all causes, from accidental trauma, drowning, SIDS, infections and chronic illnesses. The Council has long recommended improvements in the systems for provision of child welfare and support to families who are vulnerable, especially families of children with chronic illness, and these needs are magnified in the COVID-19 pandemic era.
There has in recent years been a rapid increase in the number and complexity of clinical trials and novel therapies for neurogenetic conditions. Many of these conditions are individually rare, but their impact upon affected children and their families may be very severe. While the increasing awareness and availability of new treatments brings great hope and excitement for all involved in care of these children, it also presents significant challenges for clinicians and for patients and their families.
Fortunately, COVID-19 in children is generally mild. However, the necessary public health mitigation measures to control community transmission have resulted in many unintended consequences for families and children.
How are Victorian children tracking during the pandemic? What can families do to help their children through these uncertain times? And how are young people with disabilities faring?
For several months, we have experienced significant restrictions on how we live and work. Whilst Victoria’s strict lockdown protocols are working to suppress the virus, for many of us, social isolation has taken a toll on mental health. Our new reality, and the social, mental and emotional deprivation that accompanies it, highlights that what we do in life and who we do it with, are critical to how we feel.
The COVID-19 pandemic is forcing us to re-organize and re-conceptualize many aspects of our lives. In this Grand Round, I will start with some general thoughts about these changes. Then, I will focus specifically on the challenges that the pandemic creates for the way that we oversee and regulate clinical research. I will speculate about whether some of these changes represent a better way of doing things and thus ought to change the way we practice after the pandemic.
Chimeric Antigen Receptor (CAR) T cells have revolutionised treatment for patients with acute lymphoblastic leukaemia (ALL) where standard therapies have failed. We reflect on our first 12 months as the first national paediatric referral centre providing CAR T cell treatment to children with relapsed or refractory ALL from Australia and New Zealand, and highlight the collective efforts and lessons for the hospital-wide CAR T cell team.
